Abivertinib maleate is under clinical development by Sorrento Therapeutics and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Abivertinib maleate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abivertinib maleate overview
Abivertinib maleate (AC-0010) is under development for the treatment of metastatic non small cell lung cancer, relapsed and refractory chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and other Non-Hodgkin B-Cell lymphoma such as follicular lymphoma, marginal zone lymphoma, acute respiratory distress syndrome (ARDS) in hospitalized COVID patients, Burkitt lymphoma, Waldenstrom macroglobulinemia and COVID-19 pneumonia caused by the severe acute coronavirus 2 (SARS-COV2). The drug candidate is administered through oral route in the form of capsule. The drug candidate is developed based on xCELLigence biosensor technology and proprietary small molecule library technology. It targets epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK).
It was also under development for multiple sclerosis, graft versus host disease, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer.
Sorrento Therapeutics overview
Sorrento Therapeutics (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.
For a complete picture of Abivertinib maleate’s drug-specific PTSR and LoA scores, buy the report here.